AEON Biopharma (AEON) furnishes updated corporate presentation for investors

Rhea-AI Filing Summary

AEON Biopharma, Inc. released an updated corporate investor presentation and posted it in the investor relations section of its website. The presentation, dated January 2026, is also furnished as Exhibit 99.1 and may be used by company management in future meetings about the business.

The company highlights that the presentation contains forward-looking statements and directs readers to a specific “Forward-Looking Statements” slide for important cautionary information. This disclosure is furnished under Regulation FD and is explicitly not treated as filed for liability purposes or automatically incorporated into other securities law documents unless specifically referenced.

0001837607false00018376072026-01-122026-01-12

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

​

Delaware	​ ​ ​	001-40021	​ ​ ​	85-3940478
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class	​ ​ ​	Trading Symbol	​ ​ ​	Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	​	AEON	​	NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

​

​

​

​

​

​

Item 7.01. Regulation FD Disclosure.

​

On January 12, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) made available in the investor relations section of its website a presentation (the “Corporate Presentation”), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information from the Corporate Presentation may also be used by the management of the Company in future meetings regarding the Company. For important information about forward-looking statements in the Corporate Presentation, see the slide titled “Forward-Looking Statements” in Exhibit 99.1 attached hereto.

​

The information furnished in this Item 7.01 of this Current Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

​

​

​

Item 9.01. Financial Statement and Exhibits.

​

(d) Exhibits.

​

​

Exhibit No.							Description
​		​					​
99.1							Corporate Presentation, dated January 2026
104		​					Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	AEON Biopharma, Inc.
Date: January 12, 2026	By:	/s/ Robert Bancroft
​	​	Robert Bancroft
​	​	Chief Executive Officer ​

​

​

​

FAQ

What did AEON (AEON) disclose in this recent SEC report?

AEON Biopharma, Inc. disclosed that it has made a new Corporate Presentation available in the investor relations section of its website and furnished the same presentation as Exhibit 99.1.

How will AEON Biopharma use the new Corporate Presentation?

The Corporate Presentation may be used by AEON Biopharma’s management in future meetings regarding the company, providing a consistent set of materials for investor and stakeholder discussions.

Does the AEON Corporate Presentation include forward-looking statements?

Yes. AEON states that the Corporate Presentation contains forward-looking statements and directs readers to the slide titled “Forward-Looking Statements” in Exhibit 99.1 for important explanatory information.

Is AEON’s Corporate Presentation considered filed for securities law purposes?

No. AEON specifies that the information in Item 7.01, including Exhibit 99.1, is furnished, not filed, and is not subject to Section 18 liabilities or incorporated into other securities law filings unless expressly referenced.

What exhibits are included with AEON Biopharma’s disclosure?

The report includes Exhibit 99.1, the Corporate Presentation dated January 2026, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the AEON Biopharma disclosure?

The disclosure was signed on behalf of AEON Biopharma, Inc. by Robert Bancroft, who is identified as the company’s Chief Executive Officer.